11/26/2012 | PP | Accentia defaults on $14.1 million non-interest bearing convertibles
|
6/21/2012 | PP | Accentia Biopharmaceuticals seals $225,000 private placement of units
|
6/7/2012 | PP | Accentia Biopharmaceuticals settles $1.5 million sale of convertibles
|
6/14/2011 | PP | Accentia Biopharmaceuticals wraps $4 million placement of convertibles
|
11/17/2010 | DD | Accentia, Biovest subsidiary emerge from Chapter 11 bankruptcy
|
11/2/2010 | DD | Accentia, Biovest debtor expect to emerge from bankruptcy on Nov. 17
|
10/27/2010 | DD | Accentia Biopharmaceuticals' amended plan gets court confirmation
|
10/26/2010 | DD | Accentia tweaks treatment for 2006 debenture holders' secured claims
|
10/25/2010 | DD | Accentia Biovest debtor granted final approval of $8 million DIP loan
|
10/14/2010 | DD | Accentia Biovest debtor granted interim access to $8 million DIP loan
|
10/12/2010 | DD | Accentia debtor Biovest seeks court OK to secure $8 million DIP loan
|
10/12/2010 | DD | Accentia Biopharmaceuticals' plan confirmation hearing continued
|
10/12/2010 | DD | Accentia Biovest debtor gets OK for $1.11 million DIP facility advance
|
10/7/2010 | DD | Accentia Biovest debtor seeks $1.11 million DIP facility advance
|
9/30/2010 | DD | Accentia Biopharmaceuticals eyes second plan hearing continuance
|
9/24/2010 | DD | Accentia, Biovest International unit report August financial results
|
9/23/2010 | DD | Accentia Biopharmaceuticals confirmation hearing continued to Sept. 30
|
9/22/2010 | DD | Accentia requests one-week continuance of plan confirmation hearing
|
9/21/2010 | DD | Accentia Biopharmaceuticals granted approval of ASM Capital settlement
|
9/15/2010 | DD | Accentia asks bankruptcy court to OK settlement with ASM Capital
|
8/26/2010 | DD | Accentia Biovest debtor granted $250,000 DIP financing advance
|
8/20/2010 | DD | Accentia, Biovest report July results; Accentia stock quoted on OTCQB
|
8/16/2010 | DD | Accentia Biopharmaceuticals posts $755,970 operating loss for quarter
|
8/13/2010 | DD | Accentia subsidiary seeks $250,000 advance under current DIP facility
|
8/3/2010 | DD | Accentia Biopharmaceuticals gets more time to seek support for plan
|
7/26/2010 | DD | Accentia BioPharmaceuticals' total funds drop to $522,064 in June
|
7/26/2010 | DD | Accentia subsidiary vaccine granted orphan drug status; stock listed
|
7/23/2010 | DD | Accentia Biopharmaceuticals wants more time to seek support for plan
|
6/8/2010 | DD | Accentia Biopharmaceuticals gets court OK of Laurus dispute settlement
|
6/7/2010 | DD | Accentia Biopharmaceuticals cash collateral use extended to July 8
|
6/1/2010 | DD | Accentia Biopharmaceuticals files plan, eyes summer emergence
|
5/14/2010 | DD | Accentia subsidiary debtor Biovest files plan, eyes summer emergence
|
4/16/2010 | DD | Accentia and Laurus settle disputes to allow bankruptcy emergence
|
4/14/2010 | DD | Accentia looks to extend exclusive plan-filing period to May 14
|
3/24/2010 | DD | Accentia creditor denied reconsideration of exclusivity extension
|
3/18/2010 | DD | Accentia: bankruptcy court gives company until April 14 to file plan
|
3/10/2010 | DD | Accentia looks to extend exclusive plan-filing period to March 24
|
3/2/2010 | DD | Accentia creditor asks court to reconsider exclusivity extension
|
2/4/2010 | DD | Accentia exclusive plan-filing period extended final time to Feb. 18
|
2/2/2010 | DD | Accentia unit to receive $2.5 million under distribution settlement
|
1/8/2010 | DD | Accentia looks to extend exclusive plan-filing period to Jan. 22
|
12/31/2009 | DD | Accentia granted final exclusive plan-filing period extension
|
12/16/2009 | DD | Accentia Biopharmaceuticals exclusive period extended to Dec. 22
|
12/4/2009 | DD | Accentia looks to extend exclusive plan-filing period to Dec. 14
|
11/20/2009 | DD | Accentia Biopharmaceuticals granted exclusivity extension to Dec. 4
|
11/17/2009 | DD | Accentia Biophamaceuticals looks to extend exclusivity through Dec. 4
|
9/10/2009 | DD | Accentia Biopharmaceuticals exclusive filing period extended to Nov. 2
|
7/23/2009 | DD | Accentia granted shorter-than-requested exclusivity extension
|
7/6/2009 | DD | Accentia Biopharmaceutical eyes exclusivity extension to find options
|
6/9/2009 | DD | Accentia Biopharmaceuticals' creditors committee loses one member
|
3/25/2009 | DD | Accentia Biopharmaceuticals' exclusive plan-filing period extended to July 8
|
2/17/2009 | DD | Accentia Biopharmaceutical requests six-month exclusivity extension to analyze options
|
1/7/2009 | DD | Accentia debtor gets court OK for $250,000 of interim financing after final hearing delayed
|
12/22/2008 | DD | Accentia debtor granted interim access to $750,000 of DIP financing; final hearing Jan. 7
|
12/4/2008 | DD | Accentia debtor requests approval of $3 million DIP facility
|
12/1/2008 | DD | Accentia unsecured creditors committee appointed
|
11/10/2008 | DDPPSS | Accentia, Biovest file Chapter 11 bankruptcy to lower operating expenses, financing costs
|
7/24/2008 | CV | Accentia files $50 million shelf
|
6/18/2008 | PP | New Issue: Accentia gives more details on $8.8 million discounted convertibles sale
|
6/17/2008 | PP | New Issue: Accentia Biopharmaceuticals to sell $8.5 million of discounted convertibles
|
6/17/2008 | PP | Market Commentary: Answers gets new investor; Bio-Extraction sells stock; Ringbolt, Harris & Harris, Accentia plan offerings
|
1/18/2008 | PP | New Issue: Accentia negotiates $8.7 million sale of convertible preferreds
|
9/21/2007 | PP | Accentia extends warrants issued in February private placement
|
3/1/2007 | PP | Market Commentary: Pico gears up to settle $104.45 million stock offering; National Coal secures $13.95 million from PIPE
|
2/28/2007 | PP | New Issue: Accentia secures $24.7 million from placement of convertibles
|
2/28/2007 | PP | Market Commentary: Accentia secures $24.7 million from convertibles offering; issuance activity soft
|
10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
10/3/2006 | PP | Market Commentary: Lumenis secures $120 million from stock offering; American Dairy wraps $18.2 million convertibles sale
|
10/2/2006 | PP | Market Commentary: Accentia stock edges up after $25 million convertibles sale; GTC to close $25 million PIPE
|
10/2/2006 | BTPP | New Issue: Accentia sells $25 million four-year exchangeable convertibles
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
8/28/2006 | BT | Accentia amends license with Mayo Clinic to develop over-the-counter sinusitis nasal sprays
|
8/28/2006 | BT | Accentia at buy by Jefferies
|
8/16/2006 | BT | Jefferies rates Accentia at buy
|
8/16/2006 | BT | Market Commentary: CV Therapeutics gains after pricing follow-on; Acadia adds again; Accentia slides
|
8/14/2006 | BT | Accentia may seek strategic options if no additional funds are found
|
7/24/2006 | BT | Accentia extends option to license all antifungals for chronic sinusitis from Mayo Clinic
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
7/19/2006 | BT | Accentia increases total overadvance to $7.5 million
|
7/10/2006 | BT | Accentia amends Harbinger loan with forebearance agreement
|
6/28/2006 | BT | Accentia preparing to begin phase 3 clinical trials of SinuNase
|
5/17/2006 | BT | Accentia at buy by Jefferies
|
5/17/2006 | PP | Market Commentary: Crosstex Energy will seal $360 million PIPE; Hana Biosciences prices $40 million direct placement
|
5/16/2006 | BTPP | New Issue: Accentia secures $8.23 million from private placement of stock
|
5/16/2006 | BT | FDA approves secondary endpoint in Biovest's phase 3 trial of BiovaxID in non-Hodgkin's lymphoma
|
5/16/2006 | PP | Market Commentary: Medivation to wrap $14.25 million deal; Accentia Biopharmaceuticals to settle $8.23 million PIPE
|
5/10/2006 | BT | Biovest's AutovaxID cleared for commercial sale
|
5/8/2006 | BT | FDA approves three aNDAs for combination pain product from Accentia
|
5/8/2006 | BT | Market Commentary: Monogram Biosciences stock jumps on $25 million Pfizer financing; Myogen releases 1Q earnings
|
5/2/2006 | BTPP | New Issue: Telesis CDE Two buys $11.5 million Accentia convertible loan from Biovax
|
4/13/2006 | BT | Jefferies puts Accentia at buy
|
4/12/2006 | BT | FDA grants Accentia Fast Track status for SinuNase
|
4/12/2006 | BT | Inyx, Accentia to promote MD Turbo for dose inhalers
|
4/11/2006 | BT | Accentia to begin shipping MD Turbo, first inhaler with breath-activated delivery, dose-counting capabilities
|
3/30/2006 | BT | Accentia: FDA approves Xodol, pain killer that combines hydrocodone, acetaminophen
|
3/2/2006 | BT | Accentia partner BioDelivery gets FDA non-approvable letter for Emezine
|
3/2/2006 | BT | Accentia reiterated at buy by Jefferies
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
2/22/2006 | BT | Accentia at buy by Jefferies
|
2/15/2006 | BT | Accentia gets buy rating from Jefferies
|
2/13/2006 | BT | Accentia subsidiary Teamm to launch new pain product this quarter
|
1/11/2006 | BT | Jefferies maintains Accentia at hold
|
1/5/2006 | BTPP | New Issue: Accentia expands Laurus facility by $2.5 million, receives $3 million bank loan
|
12/30/2005 | BT | Accentia seeking to restructure debt, obtain additional financing
|
12/30/2005 | BT | Jefferies maintains Accentia at hold
|
12/15/2005 | BT | Accentia, Mayo Clinic sign license option for sinusitis anti-fungals
|
12/8/2005 | BT | Accentia maintained by Jefferies at hold
|
12/7/2005 | BT | Jefferies initiates Accentia at hold rating
|
12/6/2005 | BT | Accentia licenses steroid nasal spray from Collegium to market in United States for allergic rhinitis
|
12/1/2005 | BT | Accentia says BiovaxID phase 2, 3 trials show positive results for patients with lymphoma
|
11/29/2005 | BT | Accentia test to diagnose chronic sinusitis enters commercial market
|
10/28/2005 | BT | New Issue: Accentia completes $19.2 million IPO at $8 per share, low end of sweetened talk of $8-$10
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
9/7/2005 | BT | Market Commentary: ID Biomedical climbs 13% on Glaxo acquisition; Chiron still rising; Nektar zooms over 10%
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
9/2/2005 | BT | Accentia Biopharmaceuticals lowers IPO to 2.5 million shares from 5.25 million
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
7/29/2005 | BT | Market Commentary: Advanced Life Sciences, Avalon IPOs delayed; ZymoGenetics on deck for Wed; stem cell names rise
|
7/21/2005 | BT | Market Commentary: Adams IPO zooms; Accentia stalls, again; Guilford up on MGI Pharma merger; Momenta on tap; Isis rises
|
7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
7/15/2005 | BT | Accentia delays IPO until next week, market anticipates another price range cut
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
7/11/2005 | BT | Accentia Biopharmaceuticals lowers IPO price talk to $8 to $10 per share
|
7/11/2005 | BT | Market Commentary: Accentia runs into resistance; Canadian biotechs tap PIPEs; eyes on Genentech; Mylan up
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
7/7/2005 | BT | Market Commentary: Accentia delays IPO on positive news; Salix takes off; Millipore gains; Sepracor off; Amgen soars
|
7/7/2005 | BT | Accentia delays IPO until next week or the following after receiving favorable FDA ruling
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|